Sagimet Biosciences Inc. Segments Disclosure
10. | Segment Reporting |
Operating segments are defined as components of an entity about which discrete financial information is evaluated regularly by the CODM in deciding how to allocate resources and assess performance. The Company operates and manages its business as one business segment, which is development and commercialization of therapeutics for the treatment of MASH, acne and other diseases where FASN plays a pathogenic role. Accordingly, the Company has one reportable segment. The Company has a single management team that reports to the Chief Executive Officer, the Company's CODM, who comprehensively manages the entire Company. The accounting policies of the segment are the same as those described in the summary of significant accounting policies.
When evaluating the Company’s financial performance, the CODM is regularly provided with more detailed expense information than what is included in the Company’s statements of operations and comprehensive loss. The CODM uses net loss, as reported in the
statements of operations and comprehensive loss, in evaluating the performance of the segment. Decisions regarding resource allocation are made primarily during the annual budget planning process and reallocated as needed throughout the year. The measure of segment assets is reported on the balance sheets as total assets.
The following table shows the Company’s segment net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under U.S. GAAP, for the years ended December 31, 2025, and 2024 (in thousands):
Years Ended December 31, | ||||||
2025 | | 2024 | ||||
Denifanstat external research and | $ | 28,248 | $ | 33,838 | ||
TVB-3567 external research and development |
| 6,084 |
| 810 | ||
External general and administrative expenses | 8,760 | 8,001 | ||||
Personnel costs | 7,150 | 6,517 | ||||
Stock-based compensation |
| 6,449 |
| 5,288 | ||
Other segment items (1) | (5,653) | (8,887) | ||||
Segment net loss | $ | 51,038 | $ | 45,567 | ||
___________
| (1) | Other segment items consist of (i) interest and other income, net and (ii) other internal operating research and development expenses. |
Want the next Sagimet Biosciences Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Sagimet Biosciences Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 11, 2026 | Showing above |
| 2024 | Mar 12, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.